Lung Cancer

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.

Adjuvant Erlotinib May Benefit Patients With Early-Stage Non-Small Cell Lung Cancer

Adjuvant Erlotinib May Benefit Patients With Early-Stage Non-Small Cell Lung Cancer

By

Researchers found that recurrences were rare for patients receiving adjuvant erlotinib.

Percutaneous Microwave Thermal Ablation May be Effective in Primary Lung Malignancy

Percutaneous Microwave Thermal Ablation May be Effective in Primary Lung Malignancy

By

Researchers reported that ablation of pulmonary malignant tumors may be a safe treatment option in select patients.

MET-Inhibitor Combination Shows Activity in <i>EGFR</i>-Mutated, MET-Dysregulated NSCLC

MET-Inhibitor Combination Shows Activity in EGFR-Mutated, MET-Dysregulated NSCLC

By

Combination therapy showed activity in epidermal growth factor receptor-mutated, mesenchymal-epithelial transition factor-dysregulated non-small-cell lung cancer.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers

Trials, Collaboration Might Help Reduce Survival Disparities Between Community, Academic Cancer Centers

By

Better collaboration between community and academic cancer centers could benefit patients.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Checkpoint Inhibitor Pneumonitis in NSCLC

Checkpoint Inhibitor Pneumonitis in NSCLC

By

Immune checkpoint inhibitor pneumonitis is a potentially serious complication that may occur more in patients with lung cancer than previously suspected.

Further Development of Hsp90 Inhibitor in NSCLC Remains Uncertain

Further Development of Hsp90 Inhibitor in NSCLC Remains Uncertain

By

This trial in NSCLC was terminated early when the investigational drug become unavailable following the dissolution of a partnership between the drug's codevelopers.

ctDNA Helped Predict Response, Survival After Durvalumab in Lung, Bladder Cancer

ctDNA Helped Predict Response, Survival After Durvalumab in Lung, Bladder Cancer

By

Analyzing ctDNA following drug treatment could help identify nonresponders to immunotherapy.

Efforts Made in the 1960s to Curb Smoking Will Have Effects Well Into Future

Efforts Made in the 1960s to Curb Smoking Will Have Effects Well Into Future

By

Scientific models project a continued decrease in lung cancer mortality.

Management of Hyperprogressive Disease in Nivolumab-Treated Lung Cancer

Management of Hyperprogressive Disease in Nivolumab-Treated Lung Cancer

By

Management strategies were identified for lung cancer patients who experienced hyperprogressive disease during treatment with nivolumab.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

By

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

By

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

First-Line Alectinib Effective in Asian Patients With <i>ALK</i>-Positive Advanced NSCLC

First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC

By

Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.

Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer

Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer

By

Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.

Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib

Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib

By

The 2 most common resistance mechanisms were MET amplification, EGFR C797S mutation.

Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib

Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib

By

Brigatinib significantly delayed time to intracranial progression and prolonged PFS compared with crizotinib in patients with ALK+ NSCLC with intracranial metastases.

Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers

Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers

By

Approximately one-third of patients with NSCLC with a therapeutically targetable mutation detected in plasma were able to avoid invasive biopsy.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

By

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

By

Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.

Only One-Third of Trials Supporting FDA Approval of Cancer Drugs Met the ESMO-MCBS Criteria for Substantial Clinical Benefit

Only One-Third of Trials Supporting FDA Approval of Cancer Drugs Met the ESMO-MCBS Criteria for Substantial Clinical Benefit

By

The only single-arm cancer trials to show a substantial benefit were those for osimertinib for T790-mutated NSCLC and crizotinib for ALK-rearranged NSCLC.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

By

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

By

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Perspectives on Combination Immunotherapy in NSCLC

Perspectives on Combination Immunotherapy in NSCLC

By

Many immunotherapy-based combinations are being studied in NSCLC, with TMB emerging as a potential predictive biomarker.

CT Screening Reduces Lung Cancer Deaths in High-Risk Asymptomatic Patients

CT Screening Reduces Lung Cancer Deaths in High-Risk Asymptomatic Patients

By

CT lung cancer screening substantially reduces lung cancer deaths among asymptomatic patients at high risk for developing lung cancer.

Tislelizumab Shows Antitumor Activity in Lung Cancer

Tislelizumab Shows Antitumor Activity in Lung Cancer

By

Tislelizumab, an anti-PD-1 antibody, demonstrated antitumor activity in phase 1 and phase 2 trials of Chinese patients with advanced lung cancers.

A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy

A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy

By

Humans are used to seeing canines used as tools in forensics — their skills are often harnessed to smell out drugs or trail a criminal. Some dogs are even used to locate household pests. The use of canines to detect lung cancer from smell alone, however, is a new prospect for oncologists and their patients.

Large, Upfront Assay Sped Genomic Results, Targeted Treatments in NSCLC

Large, Upfront Assay Sped Genomic Results, Targeted Treatments in NSCLC

By

In 18% of advanced lung adenocarcinoma cases, the assay identified FDA-approved or NCCN guideline-recommended targeted therapies for patients.

MET Inhibitor Shows Antitumor Activity in Advanced NSCLC

MET Inhibitor Shows Antitumor Activity in Advanced NSCLC

By

Interim data from a phase 2 trial suggests that MET inhibitor tepotinib has antitumor activity and a tolerable safety profile in advanced MET exon 14 skipping mutated NSCLC.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs